Epiphysiolysis of the hip

Summary

Epiphysiolysis of the hip (MONDO:0018382) is a disease and 17 clinical trials. Top therapeutic interventions include methyclothiazide. A subtype of osteonecrosis of genetic origin — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Clinical trials: 17

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	epiphysiolysis of the hip
Mondo ID	MONDO:0018382
MeSH	D060048
OMIM	182260
Orphanet	399329
ICD-10-CM	M93.0
SNOMED CT	26460006
UMLS	C0149887
MedGen	57704
GARD	0021666
Is cancer (heuristic)	no

Also known as: epiphysiolysis capitis femoris · epiphysiolysis of the upper femur · femoral head epiphysiolysis · SCFE · slipped capital femoral epiphysis · slipped femoral capital epiphyses · slipped upper femoral epiphysis · SUFE · SufE

Disease family

This is a subtype of osteonecrosis of genetic origin. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › osteonecrosis of genetic origin › epiphysiolysis of the hip

Related subtypes (11): Legg-Calve-Perthes disease, Thiemann disease, familial form, Scheuermann disease, Gaucher disease type I, dihydropyrimidine dehydrogenase deficiency, familial avascular necrosis of femoral head, pseudohypoparathyroidism type 1C, hereditary thrombophilia due to congenital histidine-rich (poly-L) glycoprotein deficiency, hereditary antithrombin deficiency, osteochondritis dissecans, short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 17.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	11
Not specified	4
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00208364	PHASE4	TERMINATED	A Two Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Metal-on-Metal Bearing in Primary Total Hip Replacement
NCT00208377	PHASE4	TERMINATED	A Multi-centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery
NCT00208390	PHASE4	TERMINATED	A Multi-centre Study to Assess the Long-term Performance of the Summit™ Hip in Primary Total Hip Replacement
NCT00208429	PHASE4	WITHDRAWN	A Multi-centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Polyethylene-on-metal Bearing in Primary Total Hip Replacement
NCT00208442	PHASE4	COMPLETED	A Randomised Single Centre Study to Compare the Long-term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement
NCT00872066	PHASE4	COMPLETED	A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement
NCT00872222	PHASE4	TERMINATED	A Single Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement
NCT00872547	PHASE4	TERMINATED	Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement
NCT00872573	PHASE4	TERMINATED	A Two Centre Study to Assess the Stability and Long-term Performance of the C-Stem™ AMT in a Total Primary Hip Replacement
NCT00872794	PHASE4	TERMINATED	A Single Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery
NCT00873444	PHASE4	TERMINATED	A Randomised Study to Compare Metal Ion Release and Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-Metal or a Metal-on-Metal Bearing
NCT00208351	PHASE3	TERMINATED	A Randomised Single Centre Study to Compare the Long-term Performance of 4 Designs of the DePuy Ultima LX Stem in Primary Total Hip Replacement
NCT00208468	PHASE3	TERMINATED	A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement
NCT04117841	Not specified	RECRUITING	SCFE Longitudinal International Prospective Registry
NCT01220882	Not specified	UNKNOWN	Evaluation of Skeletal Maturity for Slipped Capital Femoral Epiphysis
NCT03229590	Not specified	UNKNOWN	Slipped Capital Femoral Epiphysis Treatment
NCT05758051	Not specified	COMPLETED	Management of Slipped Capital Femoral Epiphysis (SCFE) on Top of Fixed Fracture Neck of Femur Case Report.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
METHYCLOTHIAZIDE	4	1